Marks Group Wealth Management’s West Pharmaceutical WST Stock Holding History

Marks Group Wealth Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$390K	Buy	+1,087	New	+$332K	0.03%	293

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Marks Group Wealth Management's WST Position: Q2 2026 in Review

Marks Group Wealth Management opened a new position in West Pharmaceutical (WST) in Q2 2026: 1,087 shares worth $390K. The stake represents 0.03% of the portfolio and ranks #293 among its holdings.

830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

Marks Group Wealth Management held 1,087 shares of West Pharmaceutical worth $390K as of Q2 2026.
West Pharmaceutical was a new Marks Group Wealth Management position in Q2 2026.
West Pharmaceutical made up 0.03% of Marks Group Wealth Management's portfolio in Q2 2026, its #293 holding.
830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Marks Group Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.